QRG Capital Management Inc. Has $8.19 Million Stake in Zoetis Inc. $ZTS

QRG Capital Management Inc. reduced its position in Zoetis Inc. (NYSE:ZTS) by 6.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 65,128 shares of the company’s stock after selling 4,747 shares during the quarter. QRG Capital Management Inc.’s holdings in Zoetis were worth $8,194,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Global Wealth Strategies & Associates bought a new position in Zoetis in the fourth quarter valued at approximately $25,000. KERR FINANCIAL PLANNING Corp bought a new stake in Zoetis during the third quarter worth $31,000. Lodestone Wealth Management LLC bought a new stake in Zoetis during the fourth quarter worth $30,000. Holos Integrated Wealth LLC acquired a new stake in shares of Zoetis in the 4th quarter valued at $32,000. Finally, Board of the Pension Protection Fund bought a new position in shares of Zoetis in the 4th quarter valued at $38,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Down 0.1%

Shares of NYSE:ZTS opened at $112.60 on Wednesday. Zoetis Inc. has a 52-week low of $111.27 and a 52-week high of $172.23. The company has a market capitalization of $47.36 billion, a PE ratio of 18.70, a price-to-earnings-growth ratio of 1.73 and a beta of 0.87. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The company has a fifty day moving average of $119.61 and a 200-day moving average of $124.33.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter last year, the business posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities analysts predict that Zoetis Inc. will post 7.01 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.9%. Zoetis’s dividend payout ratio is currently 35.22%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ZTS shares. Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Bank of America lifted their target price on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. William Blair reissued an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Finally, Citigroup initiated coverage on shares of Zoetis in a research note on Wednesday, April 15th. They issued a “buy” rating and a $145.00 price target on the stock. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $151.75.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.